focus -WSS

focus

author：knowledge 2025-10-02 22:57:58 - browse：2

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Intermittent fasting comes with a heart risk? Not so fast

focus

WSS

Leading voice in opioid treatment defends methadone clinic system

U.K. researchers warn about biases in medical devices, algorithms

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Colonoscopy prep: Liquid

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Moderna hits safety problems in bold bid to reinvent medicine

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

Physicians and social media: If you see something, say something?

Drug repurposing or repositioning? The language matters

The UK government moves asylum

Medical records are filled with copy

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Moonlake's readout produced a cash windfall. Risks remain

U.K. researchers warn about biases in medical devices, algorithms

Medicare details structure of new drug price negotiation program

Health AI adoption puts security, privacy startups on investors' radar

hotspot

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Orchard's therapy for neuron disease in children wins FDA approval

UnitedHealth increases loan offers after Change Healthcare outage

Mississippi candidates for statewide offices square off in party primaries

NYC plans to house migrants on an island in the East River

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

hotspot

knowledge

focus

focus